# RAMP 301 (NCT06072781)

> A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06072781
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Verastem, Inc.
- Conditions: Low Grade Serous Ovarian Cancer
- Interventions: avutometinib; Defactinib; Pegylated liposomal doxorubicin; Paclitaxel; Letrozole; Anastrozole
- Enrollment: 270
- Primary outcome: Progression Free Survival (PFS) per blinded independent central review (BICR)

## Commentary we found

- Podcasts: 11
- YouTube: 10
- X threads: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=ramp-301-nct06072781

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06072781", "email": "<work email>"}; the inbox owner confirms by the emailed link.